PURA Confirms and Clarifies Exclusivity of Patented Cannabis Extraction Process

Dallas, TX -- April 24, 2020 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) confirms and clarifies the exclusivity of its license to a patented cannabis extraction process.

Earlier today the company reported on its continuing progress in the rebranding of its recently acquired Hemp4mula CBD confections business that includes CBD infused gummies and gum. 

The earlier release highlighted a recent Grand View Research, Inc. report that the global CBD gummies market is expected to reach $6.94 Billion by 2025. 

Puration’s rebranding strategy centers on emphasizing the U.S. Patent and extensive university medical research backing Puration’s gummies and gum.

Puration has the only license of the NCM Biotech patented extraction process and that license is exclusive for the applications with edibles and beverages.  NCM Biotech is focused on medical research and Puration has access to that research, but no plans to enter the pharmaceutical market. 

The benefits of the rebranded Hemp4mula gummies and gum will be backed by NCM Biotech’s patented extraction process and university medical research making Puration’s gummies and gum a standout in the global market.

See a recent research report on CBD extracts derived from NCM Biotech’s patented extraction process: Journal of Cannabis Research

For more information on Puration, visit http://www.purationinc.com

Disclaimer/Safe Harbor: 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. 

Contact:
Puration, Inc.
Brian Shibley,
[e-mail]
[phone]